Cargando…

Linked Clusters of SARS-CoV-2 Variant B.1.351 — Maryland, January–February 2021

Detalles Bibliográficos
Autores principales:	Feder, Kenneth A., Pearlowitz, Marcia, Goode, Alexandra, Duwell, Monique, Williams, Thelonious W., Chen-Carrington, Ping An, Patel, Ami, Dominguez, Catherine, Keller, Eric N., Klein, Liore, Rivera-Colon, Alessandra, Mostafa, Heba H., Morris, C. Paul, Patel, Neil, Schauer, Anna M., Myers, Robert, Blythe, David, Feldman, Katherine A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Centers for Disease Control and Prevention 2021
Materias:	Full Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8084129/ https://www.ncbi.nlm.nih.gov/pubmed/33914724 http://dx.doi.org/10.15585/mmwr.mm7017a5

Ejemplares similares

Case series of four re-infections with a SARS-CoV-2 B.1.351 variant, Luxembourg, February 2021
por: Staub, Thérèse, et al.
Publicado: (2021)

Linked transmission chains of imported SARS-CoV-2 variant B.1.351 across mainland France, January 2021
por: Calba, Clémentine, et al.
Publicado: (2021)

Vaccine breakthrough infection and onward transmission of SARS-CoV-2 Beta (B.1.351) variant, Bavaria, Germany, February to March 2021
por: Kroidl, Inge, et al.
Publicado: (2021)

COVID-19 rise in Bangladesh correlates with increasing detection of B.1.351 variant
por: Saha, Senjuti, et al.
Publicado: (2021)

Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice
por: Martinez, David R., et al.
Publicado: (2021)

Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice
por: Martinez, David R., et al.
Publicado: (2021)

Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351
por: Shen, Xiaoying, et al.
Publicado: (2021)

The SARS-CoV-2 B.1.351 Variant Can Transmit in Rats But Not in Mice
por: Zhang, Cheng, et al.
Publicado: (2022)

Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant
por: Edara, Venkata Viswanadh, et al.
Publicado: (2021)

Four COVID-19 Cases of New Variant B.1.351 First Emerging in South Africa in Chinese Passengers on Same Flight — Shenzhen, China, January 2021
por: Cheng, Cong, et al.
Publicado: (2021)

The Impact on Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus
por: Kim, Yeong Jun, et al.
Publicado: (2021)

Detection of B.1.351 SARS-CoV-2 Variant Strain — Zambia, December 2020
por: Mwenda, Mulenga, et al.
Publicado: (2021)

Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant
por: Shinde, Vivek, et al.
Publicado: (2021)

The headache registry of the German Migraine and Headache Society (DMKG): baseline data of the first 1,351 patients
por: Ruscheweyh, Ruth, et al.
Publicado: (2022)

Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques
por: Yu, Jingyou, et al.
Publicado: (2021)

SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies
por: Hoffmann, Markus, et al.
Publicado: (2021)

The Infection and Pathogenicity of SARS-CoV-2 Variant B.1.351 in hACE2 Mice
por: Chen, Qi, et al.
Publicado: (2021)

Early detection of community acquired of SARS-CoV-2 lineage B.1.351 in Hong Kong
por: Tsang, Alan K.L., et al.
Publicado: (2021)

Infection with the SARS-CoV-2 B.1.351 variant is lethal in aged BALB/c mice
por: Yasui, Fumihiko, et al.
Publicado: (2022)

Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7
por: Wang, Pengfei, et al.
Publicado: (2021)

Correction: The headache registry of the German Migraine and Headache Society (DMKG): baseline data of the first 1,351 patients
por: Ruscheweyh, Ruth, et al.
Publicado: (2022)

Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 Protein Vaccine
por: Dayan, Gustavo H., et al.
Publicado: (2023)

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera
por: Zhou, Daming, et al.
Publicado: (2021)

Effects of B.1.1.7 and B.1.351 on COVID-19 Dynamics: A Campus Reopening Study
por: Linka, Kevin, et al.
Publicado: (2021)

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
por: Madhi, Shabir A., et al.
Publicado: (2021)

SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies
por: Moyo-Gwete, Thandeka, et al.
Publicado: (2021)

Functional Effects of Receptor-Binding Domain Mutations of SARS-CoV-2 B.1.351 and P.1 Variants
por: Bayarri-Olmos, Rafael, et al.
Publicado: (2021)

Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization
por: Wang, Pengfei, et al.
Publicado: (2021)

Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351)
por: Moyo-Gwete, Thandeka, et al.
Publicado: (2021)

Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants
por: Du, Shuo, et al.
Publicado: (2021)

Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants
por: Abu-Raddad, Laith J., et al.
Publicado: (2021)

Descriptive epidemiology of SARS‐CoV‐2 Beta (B.1.351) variant cases in England, December 2020 to June 2022
por: Sinnathamby, Mary A., et al.
Publicado: (2023)

Errata in January and February Nos
Publicado: (1868)

Subtle differences in the pathogenicity of SARS-CoV-2 variants of concern B.1.1.7 and B.1.351 in rhesus macaques
por: Munster, Vincent J., et al.
Publicado: (2021)

Subtle differences in the pathogenicity of SARS-CoV-2 variants of concern B.1.1.7 and B.1.351 in rhesus macaques
por: Munster, Vincent J., et al.
Publicado: (2021)

COVID vaccine efficacy against the B.1.351 (“South African”) variant—The urgent need to lay the groundwork for possible future challenge studies
por: Eyal, Nir, et al.
Publicado: (2021)

Tracking the international spread of SARS-CoV-2 lineages B.1.1.7 and B.1.351/501Y-V2 with grinch
por: O'Toole, Áine, et al.
Publicado: (2021)

SARS-CoV-2 B.1.1.7 and B.1.351 Spike variants bind human ACE2 with increased affinity
por: Ramanathan, Muthukumar, et al.
Publicado: (2021)

Introduction of SARS-CoV-2 variant of concern 20h/501Y.V2 (B.1.351) from Malawi to Italy
por: Novazzi, Federica, et al.
Publicado: (2021)

A human antibody of potent efficacy against SARS-CoV-2 in rhesus macaques showed strong blocking activity to B.1.351
por: Gu, Chunyin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dn0lsd87fgf5v9eipsfstv9iif